To date, although carried out in cancer patients, clinical trials of small-molecule SHP-1 inhibitors remain restricted to phase I dosing studies, and therefore anti-tumour effects, although measured, were not the primary purpose of the studies. This evidence concerns the gene NR0B2 and cancer.